Robert McNamara Biography and Net Worth

Director of Avita Medical

Mr. McNamara is an accomplished senior executive with over 25 years of leadership experience in public and privately held companies in the medical device and technology industries. His extensive experience in operations and financial management spans across early stage, high growth, and mature companies. He is currently a member of the Board of Directors and Chair of Audit Committee for Axonics, Inc. and is a member of the Board of Directors and Chair of Compensation Committee for Xtant Medical Holdings. Prior to these appointments, Mr. McNamara served as Executive Vice President, Chief Financial Officer of LDR Holding/Spine. Prior to this role, he served as the Chief Financial Officer of three publicly-traded medical device companies Accuray, Somnus Medical Technologies, and Target Therapeutics. Mr. McNamara holds a Bachelor of Science in Accounting from the University of San Francisco and an MBA from The Wharton School, University of Pennsylvania.

What is Robert McNamara's net worth?: The estimated net worth of Robert McNamara is at least $699.81 thousand as of August 28th, 2025. Mr. McNamara owns 86,771 shares of Avita Medical stock worth more than $699,808 as of August 10th. This net worth estimate does not reflect any other investments that Mr. McNamara may own. Learn More about Robert McNamara's net worth.
How do I contact Robert McNamara?: The corporate mailing address for Mr. McNamara and other Avita Medical executives is 28159 Avenue Stanford Suite 220, Valencia CA, 91355. Avita Medical can also be reached via phone at (833) 462-8482 and via email at [email protected]. Learn More on Robert McNamara's contact information.
Has Robert McNamara been buying or selling shares of Avita Medical?: Robert McNamara has not been actively trading shares of Avita Medical within the last three months. Most recently, on Thursday, August 28th, Robert Mcnamara bought 10,000 shares of Avita Medical stock. The stock was acquired at an average cost of $4.50 per share, with a total value of $45,000.00. Following the completion of the transaction, the director now directly owns 86,771 shares of the company's stock, valued at $390,469.50. Learn More on Robert McNamara's trading history.
Who are Avita Medical's active insiders?: Avita Medical's insider roster includes Suzanne Crowe (Director), Robert McNamara (Director), David O'Toole (CFO), Michael Perry (CEO), and Joseph Woody (Director). Learn More on Avita Medical's active insiders.
Are insiders buying or selling shares of Avita Medical?: In the last year, Avita Medical insiders bought shares 10 times. They purchased a total of 64,200 shares worth more than $281,190.00. The most recent insider tranaction occured on June, 9th when Director Joseph Fralin Woody bought 10,000 shares worth more than $41,900.00. Insiders at Avita Medical own 2.2% of the company. Learn More about insider trades at Avita Medical.
Information on this page was last updated on 6/9/2026.

Robert McNamara Insider Trading History at Avita Medical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/28/2025	Buy	10,000	$4.50	$45,000.00	86,771
8/19/2025	Buy	10,000	$5.00	$50,000.00	76,771
2/20/2025	Buy	10,000	$10.09	$100,900.00	45,749

Robert McNamara Buying and Selling Activity at Avita Medical

Avita Medical Company Overview

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.

Today's Range

Now: $7.85

$7.39

$8.35

50 Day Range

MA: $4.47

$3.91

$7.77

2 Week Range

Now: $7.85

$3.22

$8.35

Volume

575,447 shs

Average Volume

302,917 shs

Market Capitalization

$241.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.86